-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明，无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
HUTCHMED (China) Limited (NASDAQ:HCM) Sees Large Decline in Short Interest
HUTCHMED (China) Limited (NASDAQ:HCM) Sees Large Decline in Short Interest
HUTCHMED (China) Limited (NASDAQ:HCM – Get Rating) was the target of a large decrease in short interest in September. As of September 15th, there was short interest totalling 1,760,000 shares, a decrease of 18.9% from the August 31st total of 2,170,000 shares. Based on an average trading volume of 350,900 shares, the days-to-cover ratio is currently 5.0 days.
HUTCHMED Stock Performance
Shares of HCM traded up $0.23 during mid-day trading on Friday, hitting $8.86. 444,340 shares of the company's stock were exchanged, compared to its average volume of 449,485. The firm has a fifty day moving average of $12.27 and a two-hundred day moving average of $13.25. HUTCHMED has a twelve month low of $8.37 and a twelve month high of $36.81.
Get HUTCHMED alerts:Analyst Ratings Changes
Several research analysts have weighed in on HCM shares. StockNews.com upgraded shares of HUTCHMED from a "sell" rating to a "hold" rating in a research note on Monday, August 1st. The Goldman Sachs Group increased their price target on shares of HUTCHMED from $14.00 to $16.00 and gave the stock a "neutral" rating in a research note on Tuesday, August 9th.
Institutional Inflows and Outflows
Several hedge funds have recently modified their holdings of the business. Qube Research & Technologies Ltd acquired a new position in HUTCHMED in the 1st quarter valued at $1,222,000. Capital International Investors grew its stake in HUTCHMED by 1.4% in the 4th quarter. Capital International Investors now owns 9,054,891 shares of the company's stock valued at $317,923,000 after buying an additional 128,422 shares during the last quarter. SG Americas Securities LLC grew its stake in HUTCHMED by 7.2% in the 1st quarter. SG Americas Securities LLC now owns 65,692 shares of the company's stock valued at $1,243,000 after buying an additional 4,406 shares during the last quarter. AIA Group Ltd grew its stake in HUTCHMED by 10.0% in the 1st quarter. AIA Group Ltd now owns 356,640 shares of the company's stock valued at $6,748,000 after buying an additional 32,279 shares during the last quarter. Finally, Baillie Gifford & Co. boosted its holdings in HUTCHMED by 0.5% in the 1st quarter. Baillie Gifford & Co. now owns 365,792 shares of the company's stock valued at $6,921,000 after purchasing an additional 1,724 shares during the period. Institutional investors and hedge funds own 27.37% of the company's stock.HUTCHMED Company Profile
(Get Rating)
HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC); and Fruquintinib, an inhibitor for CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and gastrointestinal and solid tumors.
Recommended Stories
- Get a free copy of the StockNews.com research report on HUTCHMED (HCM)
- EV Battery Maker Freyr Set For Major Global Expansion
- MarketBeat: Week in Review 9/26 – 9/30
- This Is A Memorable Time To Buy Into Micron Technology
- Let Paychex Stock Work Hard For You
- Declining Profits Challenge the CarMax Value Proposition
Receive News & Ratings for HUTCHMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HUTCHMED and related companies with MarketBeat.com's FREE daily email newsletter.
HUTCHMED (China) Limited (NASDAQ:HCM – Get Rating) was the target of a large decrease in short interest in September. As of September 15th, there was short interest totalling 1,760,000 shares, a decrease of 18.9% from the August 31st total of 2,170,000 shares. Based on an average trading volume of 350,900 shares, the days-to-cover ratio is currently 5.0 days.
和黄医药(中国)有限公司(纳斯达克：HCM-GET评级)是空头股数9月份大幅减持的目标。截至9月15日，空头股数共有176万股，比8月31日的217万股减少了18.9%。以350,900股的平均成交量计算，目前天数与回补比率为5.0天。
HUTCHMED Stock Performance
和黄医药股票表现
Shares of HCM traded up $0.23 during mid-day trading on Friday, hitting $8.86. 444,340 shares of the company's stock were exchanged, compared to its average volume of 449,485. The firm has a fifty day moving average of $12.27 and a two-hundred day moving average of $13.25. HUTCHMED has a twelve month low of $8.37 and a twelve month high of $36.81.
在周五午盘交易中，HCM的股价上涨了0.23美元，达到8.86美元。该公司股票成交量为444,340股，而其平均成交量为449,485股。该公司的50日移动均线切入位为12.27美元，200日移动均线切入位为13.25美元。和黄医药的12个月低点为8.37美元，12个月高位为36.81美元。
Analyst Ratings Changes
分析师评级发生变化
Several research analysts have weighed in on HCM shares. StockNews.com upgraded shares of HUTCHMED from a "sell" rating to a "hold" rating in a research note on Monday, August 1st. The Goldman Sachs Group increased their price target on shares of HUTCHMED from $14.00 to $16.00 and gave the stock a "neutral" rating in a research note on Tuesday, August 9th.
几位研究分析师对HCM的股票进行了加码。在8月1日星期一的一份研究报告中，斯托克新闻网将和黄医药的股票评级从卖出上调为持有。8月9日，周二，高盛夫妇将和黄医药股票的目标价从14.00美元上调至16.00美元，并在一份研究报告中给予该股“中性”评级。
Institutional Inflows and Outflows
机构资金流入和流出
HUTCHMED Company Profile
和黄医药公司简介
(Get Rating)
(获取评级)
HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC); and Fruquintinib, an inhibitor for CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and gastrointestinal and solid tumors.
和黄医药(中国)有限公司在香港和国际上发现、开发癌症和免疫疾病的靶向疗法和免疫疗法，并将其商业化。它在肿瘤学/免疫学和其他风险投资领域开展业务。该公司开发Savolitinib，一种治疗非小细胞肺癌(NSCLC)、乳头状细胞癌和肾癌、结直肠癌(CRC)和胃癌(GC)的抑制剂；以及Fruquintinib，一种治疗CRC、乳腺癌、GC、子宫内膜癌(EMC)、非小细胞肺癌、肝细胞癌以及胃肠道和实体肿瘤的抑制剂。
Recommended Stories
推荐故事
- Get a free copy of the StockNews.com research report on HUTCHMED (HCM)
- EV Battery Maker Freyr Set For Major Global Expansion
- MarketBeat: Week in Review 9/26 – 9/30
- This Is A Memorable Time To Buy Into Micron Technology
- Let Paychex Stock Work Hard For You
- Declining Profits Challenge the CarMax Value Proposition
- 免费获取斯托克新闻网关于和黄医药的研究报告
- 电动汽车电池制造商Freyr将在全球大举扩张
- MarketBeat：回顾一周9/26-9/30
- 这是买入美光科技的难忘时刻
- 让Paychex股票为您努力工作
- 利润下降对CarMax价值主张的挑战
Receive News & Ratings for HUTCHMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HUTCHMED and related companies with MarketBeat.com's FREE daily email newsletter.
接受《和黄医药日报》的新闻和评级-在下面输入您的电子邮件地址，即可通过MarketBeat.com的免费每日电子邮件时事通讯接收对和黄医药及相关公司的最新新闻和分析师评级的每日摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能，分享给你的好友吧